Elevation Oncology to be acquired by Concentra for $0.36/share plus CVR; CEO Ferra out

Elevation Oncology, Inc.

Merger with Concentra Biosciences: $0.36 cash per share plus contingent value right (CVR) for up to 80% of net proceeds from EO-1022.
Board unanimously recommends tender; closing requires minimum $26.4M net cash and tender of >50% of outstanding shares.
CEO Joseph Ferra terminated effective June 30; CFO Tammy Furlong appointed President and Interim CEO, receives $600K transaction bonus at closing.
Stockholders approved reverse stock split (1:10–1:50), ratified auditor CohnReznick, and elected three Class I directors.
Tang Capital Partners provides limited guaranty up to $21.4M; support agreements covering ~5.1% of shares secured.

item 1.01item 5.02item 5.07item 7.01item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

Tammy Furlong

President and Interim Chief Executive Officer

Elevation Oncology, Inc.

Effective: 2025-06-30
Filed: Jun 09, 2025 23:59 UTC

Effective as of the Separation Date, the Board appointed Tammy Furlong, age 54, the Company’s Chief Financial Officer and Principal Financial and Accounting Officer, to succeed Mr. Ferra as President and Interim Chief Executive Officer

Departed (interim)

Joseph J. Ferra, Jr.

President, Chief Executive Officer

Elevation Oncology, Inc.

Effective: 2025-06-30
Successor: Tammy Furlong
Filed: Jun 09, 2025 23:59 UTC

In connection with the Merger, the Company terminated the employment of Joseph J. Ferra, Jr., as the Company’s President, Chief Executive Officer, effective as of June 30, 2025

Source: SEC EDGAR

accession 0001104659-25-057620

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.